ONO 4578

Drug Profile

ONO 4578

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 06 Feb 2017 Discontinued - Preclinical for Solid tumours in Japan (Topical)
  • 01 Feb 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in Japan (PO) (IV) (JapicCTI173496 )
  • 01 Feb 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Japan (PO) (JapicCTI173496 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top